Blood test to help detect certain early pancreatic tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at a special analysis of your blood (called cfDNA fragmentomics) to help find and tell apart certain early pancreatic tumors. If you’re having surgery for one of the listed solid pancreatic tumors, this trial may use your blood samples to improve diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Your biopsy/pathology shows one of these: non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma, or solid pseudopapillary tumor
- You are not currently taking anti-cancer treatments before surgery (such as chemotherapy, radiation, targeted drugs, ablation, or embolization)
- You can safely have blood drawn and have no major surgical reasons you can’t proceed
- You can follow the study and come back for follow-ups, and you agree by signing consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
This study looks at blood tests to find markers that may help detect and monitor pancreatic cancer. It compares people with pancreatic cancer to those with benign pancreatic conditions and healthy volunteers.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Hear when a new Pancreatic Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.